OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
September 05, 2023
Webinar Date/Time: Wed, Oct 11, 2023 11:00 AM EDT
September 03, 2023
Excipients should be treated equally when it comes to quality management, risk assessment, and testing.
Coprocessed excipients save time and cost while improving performance in a widening array of dosage forms.
September 02, 2023
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
August 31, 2023
Extensive research on various gene editing techniques could inform the future of mRNA therapies.
Twist Bioscience is a synthetic biology and genomics company that has developed a DNA synthesis platform to industrialize the engineering of biology, which is a new method of this process by “writing” DNA on a silicon chip.
Webinar Date/Time: Thursday, September 21, 2023 at 11am ET | 10am CT | 8am PT | 4 pm BST
August 28, 2023
Webinar Date/Time: Wed, Sep 20, 2023 11:00 AM EDT
August 24, 2023
The formulation will be used to mitigate emerging infectious diseases and public health emergencies.
August 21, 2023
FDA has halted enrollment in clinical studies for Gilead Sciences’ magrolimab, a biologic treatment in development for acute myeloid leukemia.